Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Omeflex special emulsion for infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Glucose monohydrate, Sodium dihydrogen phosphate dihydrate, Omega-3-acid triglycerides, Medium-chain triglycerides, Soya bean oil, refined, Isoleucine, Leucine, Lysine hydrochloride, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Arginine, Histidine hydrochloride monohydrate, Alanine, Aspartic acid, Glutamic acid, Glycine, Proline, Serine, Sodium hydroxide, Sodium chloride, Sodium acetate trihydrate, Potassium acetate, Magnesium acetate tetrahydrate, Calcium chloride dihydrate, Zinc acetate dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Glucose monohydrate, Sodium dihydrogen phosphate dihydrate, Omega-3-acid triglycerides, Medium-chain triglycerides, Soya bean oil, refined, Isoleucine, Leucine, Lysine hydrochloride, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Arginine, Histidine hydrochloride monohydrate, Alanine, Aspartic acid, Glutamic acid, Glycine, Proline, Serine, Sodium hydroxide, Sodium chloride, Sodium acetate trihydrate, Potassium acetate, Magnesium acetate tetrahydrate, Calcium chloride dihydrate, Zinc acetate dihydrate

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Omeflex special contains fluids and substances called amino acids, electrolytes and fatty acids that are essential for the body to grow or to recover. It also contains calories in the form of carbohydrates and fats. Omeflex special is given to adults, adolescents and children older than two years. You are given Omeflex special when you are unable to eat food normally. There are many situations when this might be the case, for example when you are recovering from surgery, injuries, or burns, or when you are unable to absorb food from your stomach and gut.

2.

What you need to know before you take it

e Omeflex special

Do not use Omeflex special ● if you are allergic to any of the active substances, to egg, peanut, soybean or fish or to any of the other ingredients of this medicine (listed in section 6). ● This medicine must not be given to newborn infants, infants and toddlers under two years old. Also, do not use Omeflex special if you suffer from any of the following: ● life-threatening blood circulation problems such as those that can occur if you are in a state of collapse or shock ● heart attack or stroke ● severely impaired blood clotting function, bleeding risk (severe coagulopathy, aggravating haemorrhagic diatheses) ● blocking of blood vessels by blood clots or fat (embolism) ● severe liver failure

● ● ● ● ● ● ●

impaired bile flow (intrahepatic cholestasis) severe kidney failure in the absence of kidney replacement therapy disturbances of your body salt composition fluid deficit or excess water in your body water on your lungs (pulmonary oedema) severe heart failure certain metabolic disorders such as

  • too much lipid (fat) in the blood
  • inborn errors of amino acid metabolism
  • abnormally high blood sugar level that needs more than 6 units of insulin per hour to be controlled
  • abnormalities of metabolism that may occur after operations or injuries
  • coma of unknown origin
  • insufficient supply of oxygen to tissues
  • abnormally high acid level in the blood.

Warnings and precautions Talk to your doctor, pharmacist or nurse before using Omeflex special . Please inform your doctor if: ● you have heart, liver or kidney problems ● you suffer from certain types of metabolic disorders such as diabetes, abnormal blood fat values and disorders of your body fluid and salt composition or your acid-base balance You will be monitored closely to detect early signs of an allergic reaction (such as fever, shivering, rash, or shortness of breath) when you receive this medicine. Further monitoring and tests such as various examinations of blood samples will be applied to make sure that your body handles the administered foodstuffs properly. Your healthcare professional will also take measures to ensure that your body's fluid and electrolyte requirements are met. In addition to Omeflex special you will receive further nutrients (foodstuffs) in order to fully cover your requirements. Children This medicine must not be given to newborn infants, infants and toddlers under two years old. Other medicines and Omeflex special Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Omeflex special can interact with some other medicines. Please tell your doctor, pharmacist or nurse if you are taking or receiving any of the following: ● insulin ● heparin ● medicines that prevent undesirable blood clotting such as warfarin or other coumarin derivatives ● medicines to promote urine flow (diuretics) ● medicines to treat high blood pressure or heart problems (ACE-inhibitors and angiotensin-II-receptor antagonists) ● medicines used in organ transplants such as ciclosporin and tacrolimus

● ●

medicines to treat inflammation (corticosteroids) hormone preparations that affect your fluid balance (adrenocorticotropic hormone [ACTH]).

Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant you will receive this medicine only if the doctor or pharmacist considers it absolutely necessary for your recovery. There is no data available about the use of Omeflex special in pregnant women. Breast-feeding is not recommended for mothers on parenteral nutrition. Driving and using machines This medicine is normally given to immobile patients, e.g. in a hospital or clinic which would exclude driving or using machines. However, the medicine itself has no effect on the ability to drive and use machines. Omeflex special contains sodium This medicine contains 1.244 mg sodium (main component of cooking/table salt) in eachml. This is equivalent to 0.062% of the recommended maximum daily dietary intake of sodium for an adult. The maximum recommended daily dose of this medicinal product contains 3048 mg sodium (found in table salt). This is equivalent to 152% of the adult recommended maximum daily dietary intake for sodium. Talk to your doctor or pharmacist if you need one or more bags daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.

3.

How to take it

Omeflex special

This medicine is administered by intravenous infusion (drip), that is, through a small tube directly into a vein. This medicine will be administered through one of your large (central) veins only. The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h. Your doctor or pharmacist will decide how much of this medicine you need and for how long you will require treatment with this medicine. Use in children This medicine must not be given to newborn infants, infants and toddlers under 2 years old. Your doctor will decide how much of this medicine your child needs and for how long your child will require treatment with this medicine.

If you use more Omeflex special than you should If you have received too much of this medicine you may suffer from a so-called 'overload syndrome' and the following symptoms: ● fluid excess and electrolyte disorders ● water on your lungs (pulmonary oedema)

● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●

loss of amino acids through the urine and disturbed amino acid balance vomiting, feeling sick shivering high blood sugar level glucose in the urine fluid deficit blood much more concentrated than normal (hyperosmolality) impairment or loss of consciousness due to extremely high blood sugar enlargement of the liver (hepatomegaly) with or without jaundice (icterus) enlargement of the spleen (splenomegaly) fat deposition in the inner organs abnormal values of liver function tests reduction of red blood cell count (anaemia) reduction of white blood cell count (leucopenia) reduction of blood platelet count (thrombocytopenia) increase of immature red blood cells (reticulocytosis) rupture of blood cells (haemolysis) bleeding or a tendency to bleeding impairment of blood coagulation (as can be seen by changes of bleeding time, coagulation time, prothrombin time etc.) fever high blood fat levels loss of consciousness

If any of these symptoms occur, the infusion must be stopped immediately. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may be serious. If any of the following side effects occur, tell your doctor immediately, he will stop giving you this medicine: Rare (may affect up to 1 in 1,000 people): ● allergic reactions, for example skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing Other side effects include: Uncommon (may affect up to 1 in 100 people): ● feeling sick, vomiting, loss of appetite Rare (may affect up to 1 in 1,000 people): ● increased tendency for your blood to clot ● bluish discolouration of the skin ● shortness of breath ● headache

● ● ● ● ● ● ● ● ●

flushing reddening of skin (erythema) sweating chills feeling cold high body temperature drowsiness pain in the chest, back, bones or lumbar region decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people): ● abnormally high blood fat or blood sugar values ● high levels of acidic substances in your blood ● Too much lipid can lead to fat overload syndrome, for more information on this please see under the heading "If you use more Omeflex special than you should" in section 3. Symptoms normally disappear when the infusion is stopped. Not known (frequency cannot be estimated from the available data): ● reduction of white blood cell count (leucopenia) ● reduction of blood platelet count (thrombocytopenia) ● impaired bile flow (cholestasis) Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: ww.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Omeflex special

Keep this medicine out of the sight and reach of children. Do not store above 25 °C. Do not freeze. If accidentally frozen, discard the bag. Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last date of that month. Keep the bag in the protective overwrap in order to protect from light.

6.

Contents of the pack and other information

What Omeflex special contains The active substances in the ready-for-use mixture are: from the top chamber (glucose solution) Glucose monohydrate equivalent to glucose

in 1000 ml 158.4 g 144.0 g

in 625 ml in 1250 ml in 1875 ml 99.00 g 90.00 g

198.0 g 180.0 g

297.0 g 270.0 g

Sodium dihydrogen phosphate dihydrate Zinc acetate dihydrate from the middle chamber (fat emulsion) Medium-chain triglycerides Soya-bean oil, refined Omega-3-acid triglycerides

2.496 g

1.560 g

3.120 g

4.680 g

7.024 mg

4.390 mg

8.780 mg

13.17 mg

in 1000 ml

in 625 ml in 1250 ml in 1875 ml

20.00 g 16.00 g 4.000 g

12.50 g 10.00 g 2.500 g

25.00 g 20.00 g 5.000 g

37.50 g 30.00 g 7.500 g

from the bottom chamber (amino acid solution) Isoleucine Leucine Lysine hydrochloride equivalent to lysine Methionine Phenylalanine Threonine Tryptophan Valine Arginine Histidine hydrochloride monohydrate equivalent to histidine Alanine Aspartic acid Glutamic acid Glycine Proline Serine Sodium hydroxide Sodium chloride Sodium acetate trihydrate Potassium acetate Magnesium acetate tetrahydrate Calcium chloride dihydrate

in 1000 ml 3.284 g 4.384 g 3.980 g 3.186 g 2.736 g 4.916 g 2.540 g 0.800 g 3.604 g 3.780 g 2.368 g 1.753 g 6.792 g 2.100 g 4.908 g 2.312 g 4.760 g 4.200 g 1.171 g 0.378 g 0.250 g 3.689 g 0.910 g 0.623 g

in 625 ml 2.053 g 2.740 g 2.488 g 1.991 g 1.710 g 3.073 g 1.588 g 0.500 g 2.253 g 2.363 g 1.480 g 1.095 g 4.245 g 1.313 g 3.068 g 1.445 g 2.975 g 2.625 g 0.732 g 0.237 g 0.157 g 2.306 g 0.569 g 0.390 g

in 1250 ml 4.105 g 5.480 g 4.975 g 3.982 g 3.420 g 6.145 g 3.175 g 1.000 g 4.505 g 4.725 g 2.960 g 2.191 g 8.490 g 2.625 g 6.135 g 2.890 g 5.950 g 5.250 g 1.464 g 0.473 g 0.313 g 4.611 g 1.137 g 0.779 g

Amino acid content [g] Nitrogen content [g] Carbohydrate content [g] Lipid content [g]

in 1000 ml 56.0 8 144 40

in 625 ml 35.0 5 90 25

in 1250 ml in 1875 ml 70.1 105.1 10 15 180 270 50 75

Electrolytes [mmol] Sodium Potassium Magnesium Calcium Zinc

in 1000 ml 53.6 37.6 4.2 4.2 0.03

in 625 ml 33.5 23.5 2.65 2.65 0.02

in 1250 ml 67 47 5.3 5.3 0.04

in 1875 ml 6.158 g 8.220 g 7.463 g 5.973 g 5.130 g 9.218 g 4.763 g 1.500 g 6.758 g 7.088 g 4.440 g 3.286 g 12.73 g 3.938 g 9.203 g 4.335 g 8.925 g 7.875 g 2.196 g 0.710 g 0.470 g 6.917 g 1.706 g 1.169 g

in 1875 ml 100.5 70.5 7.95 7.95 0.06

Chloride Acetate Phosphate

Energy in the form of lipids [kJ (kcal)] Energy in the form of carbohydrates [kJ (kcal)] Energy in the form of amino acids [kJ (kcal)] Non-protein energy [kJ (kcal)] Total energy [kJ (kcal)]

48 48 16

30 30 10

60 60 20

90 90 30

in 1000 ml 1590 (380) 2415 (575) 940 (225) 4005 (955)

in 625 ml 995 (240) 1510 (360) 585 (140) 2505 (600)

in 1250 ml 1990 (475) 3015 (720) 1170 (280) 5005 (1195)

in 1875 ml 2985 (715) 4520 (1080) 1755 (420) 7510 (1795)

4945 (1180)

3090 (740)

6175 (1475)

9260 (2215)

Osmolality [mOsm/kg] 2115 Theoretical osmolarity [mOsm/l] 1545 pH 5.0 – 6.0 The other ingredients are citric acid monohydrate (for pH adjustment), egg phospholipids for injection, glycerol, sodium oleate, all-rac-alpha-tocopherol, sodium hydroxide (for pH adjustment) and water for injections. What Omeflex special looks like and contents of the pack The ready-to-use product is an emulsion for infusion, i.e. it is administered through a small tube into a vein. Omeflex special is supplied in flexible multichamber bags containing: ● 625 ml (250 ml of amino acids solution + 125 ml of fat emulsion + 250 ml of glucose solution) ● 1250 ml (500 ml of amino acids solution + 250 ml of fat emulsion + 500 ml of glucose solution) ● 1875 ml (750 ml of amino acids solution + 375 ml of fat emulsion + 750 ml of glucose solution)

Figure A

Figure B

Figure A: The multichamber bag is packed in a protective overwrap. An oxygen absorber and an oxygen indicator are placed between the bag and the overwrap; the oxygen absorber sachet is made of inert material and contains iron hydroxide. Figure B: The top chamber contains a glucose solution, the middle chamber contains a fat emulsion, and the bottom chamber contains an amino acid solution. The glucose and the amino acid solutions are clear and colourless up to straw-coloured. The fat emulsion is milky white. The top chamber and the middle chamber can be connected with the bottom chamber by opening the intermediate seams.

The different container sizes are presented in cartons containing five bags. Pack sizes: 5 x 625 ml, 5 x 1250 ml and 5 x 1875 ml Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer B. Braun Melsungen AG Carl-Braun-Straße 1 34212 Melsungen, Germany

Postal address: 34209 Melsungen, Germany

Phone: +49-5661-71-0 Fax: +49-5661-71-4567

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (GB and NI) under the following names: Austria Nutriflex Omega special B.Braun Emulsion zur Infusion Belgium Nutriflex Omega special 56 g/l Amino + 144g/l G, emulsie voor infusie Bulgaria Nutriflex Omega 56/144 special emulsion for infusion Croatia Nutriflex Omega 56/144 specijal emulzija za infuziju Czech Republic Nutriflex Omega special 56/144

Denmark Estonia Finland France Germany Greece Ireland Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (GB and NI)

Nutriflex Omega Special Nutriflex Omega 56/144 infusiooniemulsioon Nutriflex Omega 56/144/40 infuusioneste, emulsio REANUTRIFLEX OMEGA E, émulsion pour perfusion NuTRIflex Omega special novo Emulsion zur Infusion Nutriflex Omega 56/144 special Omeflex special emulsion for infusion Omegaflex AA56/G144 emulsione per infusione Nutriflex Omega 56/144 emulsija infūzijām Nutriflex Omega 56/144 infuzinė emulsija NuTRIflex Omega special novo Emulsion zur Infusion Nutriflex Omega special, 56 g/l Amino + 144 g/l G, emulsie voor infusie Nutriflex Omega Special infusjonsvæske, emulsjon Omegaflex special Nutriflex Omega 56/144 S emulsão para perfusão NuTRIflex Omega Special novo, emulsie perfuzabilă Nutriflex Omega special 56/144 Nutriflex Omega special 56/144 emulzija za infundiranje Omegaflex especial emulsión para perfusión Nutriflex Omega 56/144/40 infusionsvätska, emulsion Omeflex special emulsion for infusion

This leaflet was last revised in 07/2024 ___________________________________________________________________ The following information is intended for healthcare professionals only: Parenteral nutrition products should be visually inspected for damage, discolouration and emulsion instability before use. Do not use bags which are damaged. Overwrap, primary bag and the peel seams between the chambers should be intact. Only use if the amino acid and glucose solutions are clear and colourless up to straw-coloured and the lipid emulsion is homogenous with milky white appearance. Do not use if the solutions contain particulate matter. After mixing the three chambers, do not use if the emulsion shows discolouration or signs of phase separation (oil drops, oil layer). Stop the infusion immediately in case of discolouration of the emulsion or signs of phase separation. Before opening the overwrap, check the colour of the oxygen indicator (see Figure A). Do not use if the oxygen indicator turned pink. Use only if the oxygen indicator is yellow. Preparation of the mixed emulsion Strict adherence to aseptic handling principles must be complied with. To open: Tear overwrap starting from the tear notches (Fig. 1). Remove the bag from its protective overwrap. Discard overwrap, oxygen indicator and oxygen absorber.

Visually inspect the primary bag for leaks. Leaky bags must be discarded, since the sterility cannot be guaranteed.

Mixing of the bag and addition of additives To open and mix the chambers sequentially, roll the bag with both hands, starting first by opening the peel seam that separates the top chamber (glucose) and the bottom chamber (amino acids) (Fig. 2).

Then continue applying pressure so that the peel seam separating the middle chamber (lipids) and the bottom chamber opens (Fig. 3).

After all chambers are mixed and following the removal of the aluminium seal (Fig. 3A), one can add compatible additives via the medication port (Fig. 4). Mix the contents thoroughly (Fig. 5) and visually inspect the mixture (Fig. 6). The mixture is a milky white homogenous oil-in-water emulsion. There should be no signs of emusion phase separation.

Omeflex special can be mixed with the following additives up to the below specified upper concentration limits or maximum amount of additives after supplementation. The resulting admixtures are stable for 7 days between +2 °C to +8 °C plus 2 days at 25 °C.

  • Electrolytes: take account of the electrolytes already present in the bag; stability has been demonstrated up to a total quantity of 200 mmol/l of sodium + potassium (sum), 9.6 mmol/l of magnesium and 6.4 mmol/l of calcium in the ternary mixture.
  • Phosphate: stability has been demonstrated up to a maximum concentration of 20 mmol/l for inorganic phosphate or up to a maximum concentration of 30 mmol/l for organic phosphate (not both at the same time).
  • Alanyl-Glutamin up to 24 g/l.
  • Trace elements and vitamins: stability has been demonstrated with commercially available multi-trace elements and multi-vitamins (e.g. Tracutil, Cernevit) up to the standard dosage recommended by the respective manufacturer of the micronutrient. Detailed information about the above mentioned additives and the corresponding shelf life of such admixtures can be provided on demand by the manufacturer. Preparation for infusion The emulsion should always be brought to room temperature prior to infusion. Remove the aluminium foil from the infusion port (Fig. 7) and attach the infusion set (Fig. 8). Use a non-vented infusion set or close the air vent when using a vented set. Hang the bag on an infusion stand (Fig. 9) and carry out infusion using the standard technique.

For single use only. Container and unused residues must be discarded after use. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Do not reconnect partially used containers. If filters are used they must be lipid-permeable (pore size ≥ 1.2 μm). Shelf life after removing the protective overwrap and after mixing of the contents of the bag Chemical and physicochemical in-use stability of the mixture of amino acids, glucose and fat was demonstrated for 7 days at 2-8 °C and additional 2 days at 25 °C. Shelf life after admixture of compatible additives From a microbiological point of view, the product should be used immediately after admixture of additives. If not used immediately after admixture of additives, in-use storage times and conditions prior to use are the responsibility of the user. After first opening (spiking of the infusion port) The emulsion is to be used immediately after opening of the container. Omeflex special must not be mixed with other medicinal products for which compatibility has not been documented. Omeflex special should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination.

Frequently asked questions about Omeflex special emulsion for infusion

How do I take Omeflex special emulsion for infusion?

Omeflex special emulsion for infusion comes as infusion. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Omeflex special emulsion for infusion?

The active substance in Omeflex special emulsion for infusion is glucose monohydrate, sodium dihydrogen phosphate dihydrate, omega-3-acid triglycerides, medium-chain triglycerides, soya bean oil, refined, isoleucine, leucine, lysine hydrochloride, methionine, phenylalanine, threonine, tryptophan, valine, arginine, histidine hydrochloride monohydrate, alanine, aspartic acid, glutamic acid, glycine, proline, serine, sodium hydroxide, sodium chloride, sodium acetate trihydrate, potassium acetate, magnesium acetate tetrahydrate, calcium chloride dihydrate, zinc acetate dihydrate.

Are there equivalent medicines to Omeflex special emulsion for infusion?

Medicines with the same active substance, strength and form include: Omeflex peri emulsion for infusion, Omeflex plus emulsion for infusion. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Omeflex special emulsion for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Omeflex special emulsion for infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

  • Source: electronic medicines compendium (emc), Datapharm
  • Active substance: glucose monohydrate, sodium dihydrogen phosphate dihydrate, omega-3-acid triglycerides, medium-chain triglycerides, soya bean oil, refined, isoleucine, leucine, lysine hydrochloride, methionine, phenylalanine, threonine, tryptophan, valine, arginine, histidine hydrochloride monohydrate, alanine, aspartic acid, glutamic acid, glycine, proline, serine, sodium hydroxide, sodium chloride, sodium acetate trihydrate, potassium acetate, magnesium acetate tetrahydrate, calcium chloride dihydrate, zinc acetate dihydrate
  • Official document: view the original leaflet on emc →
Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Supply of energy, essential fatty acids including omega-3 and omega-6 fatty acids, amino acids, electrolytes and fluids for parenteral nutrition of patients in states of moderate to severe catabolism when oral or enteral nutrition is impossible, insufficient or contraindicated.

Omeflex special is indicated in adults, adolescents and children older than two years.

4.2. Posology and method of administration

Posology

The dosage should be adapted to the patients' individual requirements.

It is recommended that Omeflex special be administered continuously. A stepwise increase of the infusion rate over the first 30 minutes up to the desired infusion rate avoids possible complications.

Adults

The maximum daily dose amounts to 35 ml / kg body weight, corresponding to

2.0 g amino acids

5.04 g glucose

1.4 g lipid

/ kg body weight per day

/ kg body weight per day

/ kg body weight per day.

The maximum rate of infusion is 1.7 ml / kg body weight per hour, corresponding to

0.1 g amino acids

0.24 g glucose

0.07 g lipid

/kg body weight per day

/kg body weight per day

/kg body weight per day.

For a patient weighing 70 kg this corresponds to a maximum infusion rate of 119 ml per hour. The amount of substrate administered is then 6.8 g of amino acids per hour, 17.1 g of glucose per hour and 4.8 g of lipids per hour.

Paediatric population

Newborn infants, infants and toddlers less than two years of age

Omeflex special is contraindicated in newborn infants, infants and toddlers < 2 years of age in whom the amino acid cysteine may be considered conditionally essential (see section 4.3).

Children from 2 – 18 years of age.

No clinical studies were performed in the paediatric population.

Omeflex special can provide only a basic nutrient and energy supply to the paediatric patients. Depending on the individual need Carnitine supplementation may be considered in paediatric patients expected to receive PN for more than 4 weeks.

The exact dosage depends on the patient's energy expenditure and the ability to metabolize the active ingredients of Omeflex special and therefore, should be individually adapted according to age, body weight, clinical condition and underlying disease.

Due to the individual needs of paediatric patients, Omeflex special may not cover sufficiently the total energy, nutrient, electrolyte and fluid requirements. In such cases additional amino acids, carbohydrates and/or lipids, minerals and/or fluids must be provided in addition, as appropriate.

For calculation of dosage account must be taken of the hydration status of the paediatric patient.

The bag size should be chosen accordingly.

In addition, the daily fluid, glucose and energy requirements decrease with age. Thus, two age groups, from 2 to 12 years and 12 to 18 years, are considered.

Maximum daily dose

According to the paediatric guidelines the dose depends not only on the age but also on the medical condition (acute, stable and recovery phase) of the paediatric patient.

For Omeflex special in the age group 2 to 12 years the magnesium concentration is the limiting factor for the maximum daily dose in all medical conditions.

For patients from 12 to 18 years the glucose concentration becomes the limiting factor in the acute and stable phase while in the recovery phase the magnesium concentration is limiting.

The resulting maximum daily doses are given in the table below.

2 to ≤ 12 years

12 to 18 years

Recommended

Omeflex special

Recommended

Omeflex special

Acute phase

Stable Phase

Recovery phase

Acute phase

Stable Phase

Recovery phase

Maximum daily dose [ml/kg/d]

24

9.5

20

24

corresponding to

corresponding to

Fluids [ml/kg/d]

60 - 100

24

50 - 70

9.5

20

24

Amino acids [g/kg/d]

1.0 - 2.0 (2.5)

1.34

1.0 - 2.0

0.53

1.12

1.34

Glucose [g/kg/d]

Acute phase

1.4 – 3.6

3.46

0.7 – 1.4

1.37

-

-

Stable phase

2.2 – 5.8

1.4 – 2.9

-

2.88

-

Recovery phase

4.3 – 8.6

2.9 – 4.3

-

-

3.46

Lipids [g/kg/d]

≤ 3

0.96

≤ 3

0.38

0.8

0.96

Energy [kcal/kg/d]

Acute phase

30 - 45

28.3

20 - 30

11.2

-

-

Stable phase

40 - 60

25 - 40

-

23.6

-

Recovery phase

55 - 75

30 - 55

-

-

28.3

Sodium [mmol/kg/d]

1 - 3

1.29

1 - 3

0.51

1.07

1.29

Potassium [mmol/kg/d]

1 - 3

0.9

1 - 3

0.36

0.75

0.90

Calcium [mmol/kg/d]

0.25 - 0.4

0.10

0.25 - 0.4

0.04

0.08

0,10

Magnesium [mmol/kg/d]

0.1

0.10

0.1

0.04

0.08

0,10

Chloride [mmol/kg/d]

2 - 4

1.15

2 - 4

0.46

0.96

1.15

Phosphate [mmol/kg/d]

0.2 - 0.7

0.38

0.2 - 0.7

0.15

0.32

0.38

Acute phase = resuscitation phase when the patient requires vital organ support (sedation, mechanical ventilation, vasopressors, fluid resuscitation); Stable phase = patient is stable on, or can be weaned, from this vital support; Recovery phase = patient who is mobilizing.

For children, it might be necessary to start the nutritional therapy with half of the target dosage. The dosage should be increased stepwise according to the individual metabolic capacity up the maximum dosage.

Maximum infusion rate

According to the paediatric guidelines the maximum infusion rate depends not only on age but also on the medical condition (acute, stable and recovery phase) of the paediatric patient.

For Omeflex special the glucose infusion rate is the limiting factor for both paediatric age groups in all medical conditions.

The resulting maximum hourly infusions rates are given in the table below.

Paediatric age group

2 to ≤ 12 years

12 to 18 years

Recommended

Omeflex special

Recommended

Omeflex special

Acute phase

Stable Phase

Recovery phase

Acute phase

Stable Phase

Recovery phase

Maximum infusion rate [ml/kg/h]

0.63

1.25

1.67

0.42

0.83

1,25

corresponding to

corresponding to

Amino acids [g/kg/h]

≤ 0.1

0.035

0.07

0.094

≤ 0.1

0.024

0.046

0.07

Glucose [g/kg/h]

Acute phase

0.09

0.09

-

-

0.03 – 0.06

0.06

-

-

Stable phase

0.09 - 0.18

-

0.18

-

0.06 – 0.12

-

0.12

-

Recovery phase

0.18 - 0.24

-

-

0.24

0.12 – 0.18

-

-

0.18

Lipids [g/kg/h]

≤ 0.15

0.025

0.05

0.067

≤ 0.15

0.017

0.033

0.05

Patients with renal/hepatic impairment

The doses should be adjusted individually in patients with hepatic or renal insufficiency (see also section 4.4).

Patients with intradialytic parenteral nutrition (IDPN)

Intradialytic parenteral nutrition is intended for non-acutely ill malnourished dialysis patients where nutritional counselling or treatment with oral nutritional supplements was ineffective. The selection of the appropriate Omeflex Special volume to be used for IDPN should be guided by the gap between spontaneous intakes and the recommended intakes. Additionally, metabolic tolerance needs to be taken into consideration. For Omeflex special in patients on IDPN, the maximum hourly infusion rate is 2.3 ml/kg/hour, corresponding to 0.13 g/kg/hour amino acids, 0.33 g/kg/hour glucose, and 0.092 g/kg/hour lipids administered for 4 hours. Taking into consideration the known amino acid (retention rate 73%) and glucose losses (25g/ 4-hour dialysis session) during dialysis the patient will finally receive 0.095 g/kg/hour amino acids, 0,24 g/kg/hour glucose and 0.092 g/kg/hour lipids. For a 70 kg patient and a 4-hour dialysis session this corresponds to 27 g of amino acids, 67 g of glucose, 26 g of lipids and 644 ml of fluid.

Duration of treatment

The duration of treatment for the indications stated is not limited. During the administration of Omeflex special it is necessary to provide an appropriate amount of trace elements and vitamins.

Duration of infusion of one single bag

The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h.

Method of administration

Intravenous use. For central venous infusion only.

During intradialytic parenteral nutrition (IDPN) the bag should be administered through the venous drip chamber of the extracorporeal circulation lines.

4.3. Contraindications

● hypersensitivity to the active substances, to egg, fish, peanut or soya protein or to any of the excipients listed in section 6.1.

● inborn errors of amino acid metabolism

● severe hyperlipidaemia characterized by hypertriglyceridaemia (≥ 1000 mg/dl or 11.4 mmol/l)

● severe coagulopathy

● hyperglycaemia not responding to insulin doses of up to 6 units insulin/hour

● acidosis

● intrahepatic cholestasis

● severe hepatic insufficiency

● severe renal insufficiency in absence of renal replacement therapy

● aggravating haemorrhagic diatheses

● acute thrombo-embolic events, lipid embolism

On account of its composition Omeflex special must not be used in newborn infants, infants and toddlers under 2 years of age.

General contraindications to parenteral nutrition include:

● unstable circulatory status with vital threat (states of collapse and shock)

● acute phases of cardiac infarction and stroke

● unstable metabolic condition (e.g. severe postaggression syndrome, coma of unknown origin)

● inadequate cellular oxygen supply

● disturbances of the electrolyte and fluid balance

● acute pulmonary oedema

● decompensated cardiac insufficiency

4.4. Special warnings and precautions for use

Caution should be exercised in cases of increased serum osmolarity.

Disturbances of the fluid, electrolyte or acid-base balance must be corrected before the start of infusion.

Too rapid infusion can lead to fluid overload with pathological serum electrolyte concentrations, hyperhydration and pulmonary oedema.

Any sign or symptom of anaphylactic reaction (such as fever, shivering, rash or dyspnoea) should lead to immediate interruption of the infusion.

The serum triglyceride concentration should be monitored when infusing Omeflex special.

Depending on the patient's metabolic condition, occasional hypertriglyceridaemia may occur. If the plasma triglyceride concentration exceeds 4.6 mmol/l (400 mg/dl) during administration of lipids, it is recommended to reduce the infusion rate. The infusion must be interrupted if the plasma triglyceride concentration exceeds 11.4 mmol/l (1000 mg/dl), as these levels have been associated with acute pancreatitis.

Patients with impaired lipid metabolism

Omeflex special should be administered cautiously to patients with disturbances of lipid metabolism with increased serum triglycerides, e.g. renal insufficiency, diabetes mellitus, pancreatitis, impaired hepatic function, hypothyroidism (with hypertriglyceridaemia), sepsis, and metabolic syndrome. If Omeflex special is given to patients with these conditions, more frequent monitoring of serum triglycerides is necessary to assure triglyceride elimination and stable triglyceride levels below 11.4 mmol/l (1000 mg/dl).

In combined hyperlipidaemias and in metabolic syndrome, triglyceride levels react to glucose, lipids and overnutrition. Adjust dose accordingly. Assess and monitor other lipid and glucose sources, and drugs interfering with their metabolism.

The presence of hypertriglyceridaemia 12 hours after lipid administration also indicates a disturbance of lipid metabolism.

Like all solutions containing carbohydrates, the administration of Omeflex special can lead to hyperglycaemia. The blood glucose level should be monitored. If there is hyperglycaemia, the rate of infusion should be reduced or insulin should be administered. If the patient is receiving other intravenous glucose solutions concurrently, the amount of additionally administered glucose has to be taken into account.

An interruption of administration of the emulsion may be indicated if the blood glucose concentration rises to above 14 mmol/l (250 mg/dl) during administration.

Refeeding or repletion of malnourished or depleted patients may cause hypokalaemia, hypophosphataemia and hypomagnesaemia. Close monitoring of serum electrolytes is mandatory. Adequate supplementation of electrolytes according to deviations from normal values is necessary.

Controls of the serum electrolytes, the water balance, the acid-base balance, and of blood cell counts, coagulation status, hepatic and renal function are necessary.

Substitution of electrolytes, vitamins and trace elements may be necessary as required. As Omeflex special contains zinc, magnesium, calcium and phosphate, care should be taken when it is co-administered with solutions containing these substances.

Omeflex special should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination (see also section 4.5).

Omeflex special is a preparation of complex composition. It is, therefore, strongly advisable not to add other solutions (as long as compatibility is not proven – see section 6.2).

As with all intravenous solutions, especially for parenteral nutrition, strict aseptic precautions are necessary for the infusion of Omeflex special.

Paediatric population

There is as yet no clinical experience of the use of Omeflex special in children and adolescents.

Elderly patients

Basically the same dosage as for adults applies, but caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that may frequently be associated with advanced age.

Patients with diabetes mellitus, impaired cardiac or renal function

Like all large-volume infusion solutions, Omeflex special should be administered with caution to patients with impaired cardiac or renal function.

There is only limited experience of its use in patients with diabetes mellitus or renal failure.

This medicinal product contains 1,244 mg sodium per ml, equivalent to 0.062% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

The maximum daily dose of this product for a 70 kg adult is equivalent to 152% of the WHO recommended maximum daily intake for sodium.

Omeflex special is considered high in sodium. This should be particularly taken into account for those on a low salt diet.

Interference with laboratory tests

The fat content may interfere with certain laboratory measurements (e.g. bilirubin, lactate dehydrogenase, oxygen saturation) if blood is sampled before fat has been adequately cleared from the blood stream.

4.5. Interaction with other medicinal products and other forms of interaction

Some drugs, like insulin, may interfere with the body's lipase system. This kind of interaction seems, however, to be of only limited clinical importance.

Heparin given in clinical doses causes a transient release of lipoprotein lipase into the circulation. This may result initially in increased plasma lipolysis followed by a transient decrease in triglyceride clearance.

Soya-bean oil has a natural content of vitamin K1. This may interfere with the therapeutic effect of coumarin derivatives which should be closely monitored in patients treated with such drugs.

Potassium-containing solutions like Omeflex special should be used with caution in patients receiving drugs that increase serum potassium concentration, such as potassium-sparing diuretics (triamterene, amiloride, spironolactone), ACE inhibitors (e.g. captopril, enalapril), angiotensin-II-receptor antagonists (e.g. losartan, valsartan), ciclosporin and tacrolimus.

Corticosteroids and ACTH are associated with sodium and fluid retention.

Omeflex special should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination (see also section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of Omeflex special in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).

Parenteral nutrition may become necessary during pregnancy. Omeflex special should only be given to pregnant women after careful consideration.

Breast-feeding

Components/metabolites of Omeflex special are excreted in human milk, but at therapeutic doses no effects on the breastfed newborns/infants are anticipated. Nevertheless, breast-feeding is not recommended for mothers on parenteral nutrition.

Fertility

No data from the use of Omeflex special available.

4.7. Effects on ability to drive and use machines

Omeflex special has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Under conditions of correct use, in terms of dosing monitoring, observation of safety restrictions and instructions, undesirable effects may still occur. The following listing includes a number of systemic reactions that may be associated with the use of Omeflex special. Undesirable effects are listed according to their frequencies as follows:

Very common

Common

Uncommon

Rare

Very rare

Not known

(≥ 1/10)

(≥ 1/100 to < 1/10)

(≥ 1/1,000 to < 1/100)

(≥ 1/10,000 to < 1/1,000)

(< 1/10,000)

(frequency cannot be estimated from the available data)

Blood and lymphatic system disorders

Rare:

Hypercoagulation

Not known:

Leucopenia, thrombocytopenia

Immune system disorders

Rare:

Allergic reactions (e.g. anaphylactic reactions, dermal eruptions, laryngeal, oral and facial oedema)

Metabolism and nutrition disorders

Uncommon:

Loss of appetite

Very rare:

Hyperlipidaemia, hyperglycaemia, metabolic acidosis

The frequency of these undesirable effects is dose-dependent and may be higher under the condition of absolute or relative lipid overdose.

Nervous system disorders

Rare:

Headache, drowsiness

Vascular disorders

Rare:

Hypertension or hypotension, flush

Respiratory, thoracic and mediastinal disorders

Rare:

Dyspnoea, cyanosis

Gastrointestinal disorders

Uncommon:

Nausea, vomiting

Hepatobiliary disorders

Not known:

Cholestasis

Skin and subcutaneous tissue disorders

Rare:

Erythema, sweating

Musculoskeletal and connective tissue disorders

Rare:

Pain in the back, bones, chest and lumbar region

General disorders and administration site conditions

Rare:

Elevated body temperature, feeling cold, chills

Very rare:

Fat overload syndrome (details see below)

Should adverse reactions occur, the infusion must be stopped.

Should the triglyceride level rise to above 11.4 mmol/l (1000 mg/dl) during infusion, the infusion must be stopped. With levels above 4.6 mmol/l (400 mg/dl), the infusion may be continued at a reduced dosage (see section 4.4).

If the infusion is restarted, the patient should be carefully monitored, especially at the beginning, and serum triglycerides should be determined at short intervals.

Information on particular undesirable effects

Nausea, vomiting and lack of appetite are symptoms often related to conditions for which parenteral nutrition is indicated, and may be associated with parenteral nutrition at the same time.

Fat overload syndrome

Impaired capacity to eliminate triglycerides can lead to “fat overload syndrome” which may be caused by overdose. Possible signs of metabolic overload must be observed. The cause may be genetic (individually different metabolism) or the fat metabolism may be affected by ongoing or previous illnesses. This syndrome may also appear during severe hypertriglyceridaemia, even at the recommended infusion rate, and in association with a sudden change in the patient's clinical condition, such as renal function impairment or infection. The fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly with or without icterus, splenomegaly, anaemia, leucopenia, thrombocytopenia, coagulation disorder, haemolysis and reticulocytosis, abnormal liver function tests and coma. The symptoms are usually reversible if the infusion of the fat emulsion is discontinued. Should signs of a fat overload syndrome occur, the infusion of Omeflex special should be discontinued immediately.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

Symptoms of fluid and electrolyte overdose

Hyperhydration, electrolyte imbalance and pulmonary oedema.

Symptoms of amino acid overdose

Renal amino acid losses with consecutive amino acid imbalances, sickness, vomiting and shivering.

Symptoms of glucose overdose

Hyperglycaemia, glucosuria, dehydration, hyperosmolality, hyperglycaemic-hyperosmolar coma.

Symptoms of lipid overdose

See section 4.8.

Treatment

Immediate cessation of infusion is indicated for overdose. Further therapeutic measures depend on the particular symptoms and their severity. When infusion is recommenced after the symptoms have declined it is recommended that the infusion rate be raised gradually with monitoring at frequent intervals.

💬 Ask about this leaflet

Ask anything about Omeflex special emulsion for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →